New gene therapy found safe for treating coronary heart disease

DALLAS, August 3 -- The first human test of a gene therapy that is injected directly into the oxygen-starved heart muscle has shown the technique to be safe, opening the door to promising new treatments for heart disease, according to a report in today's Circulation: Journal of the American Heart Association.

"The implications are huge. To say anything less than that is an understatement. This addresses a tremendous problem of the large number of very sick patients for whom we can do nothing to help their coronary artery disease," says the study's lead author Todd K. Rosengart, M.D., associate professor of cardiothoracic surgery at Weill Medical College of Cornell University, New York City.

The study found no evidence that either the gene or the method used to deliver it (an inactive virus) caused any adverse side effects. "There is no evidence of inflammation, damage to the heart muscle, or viral effects," says Rosengart.

The small, preliminary study of 21 heart patients was not designed to prove the gene therapy's effectiveness. That will require further research, including clinical trials with large numbers of patients.

A build-up of fatty deposits in heart arteries reduces the flow of blood and can lead to a heart attack. Although the Cornell study was not designed to look at gene therapy's role in treating heart disease, most participants said they experienced less chest pain after the injection. A variety of tests also found that the injection led to a growth of new blood vessels, thereby improving blood flow to oxygen-starved areas of their hearts.

"We don't have enough patients to say anything definite about the effectiveness of this therapy in treating heart disease, but if you look at the trends in the data, they are all in the right direction, which is very encouraging," says Ronald G. Crystal, M.D., professor of medicine and chief of pulmonary and critical care medicine

Contact: Carole Bullock
American Heart Association

Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:

(Date:2/11/2020)... , ... February 11, 2020 ... ... to solving complex problems for life sciences companies and government agencies, announced ... years of management consulting expertise to Tunnell, with significant experience assessing, designing, ...
(Date:2/6/2020)... ... February 06, 2020 , ... ... to unique lab-made bioresearch materials, today announced an agreement with The Good ... and seafood a reality. Under the partnership, terrestrial meat and aquatic cell lines ...
(Date:1/29/2020)... ... January 29, 2020 , ... Jason Burke has joined ... practice, providing consulting services for strategy, research and development and data governance to ... and Managing Partner of CREO, an innovative management consulting and advisory firm based ...
Breaking Biology News(10 mins):
(Date:2/5/2020)... ... 2020 , ... Shoreline Biome , a microbiome research ... has announced a new distribution partnership in Asia. , The distribution partner, Gene ... and research organizations in China, Hong Kong, and Macau. , Gene Company Limited ...
(Date:1/28/2020)... (PRWEB) , ... January 28, 2020 , ... ... to be the exclusive distributor to food and beverage manufactures within North America. ... considered critical suppliers. This agreement will allow each company to pool their collective ...
(Date:1/27/2020)... ... 2020 , ... Valencell, the leading innovator in wearable biometric ... Halma plc , a FTSE 100 global group of life-saving technology companies, ... Joshua Fund. A representative from Halma will join the Valencell board of directors. ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant CEO ... industry at two recent North American investor forums specializing in medical advancements. New ... Technologies & Diagnostics Forum on November 21, 2019 in New York City, and ...
Breaking Biology Technology:
Cached News: